by Kevin Dooley, MD | Mar 30, 2021 | News and Information
Negative Results The biotech company Orphazyme announced negative results yesterday for the clinical trial of arimoclomol in the treatment of inclusion body myositis (IBM). The drug failed to meet the primary and secondary endpoints which were used to measure success....
by Kevin Dooley, MD | Aug 26, 2020 | News and Information
The Orphan Disease Center 2020 Million Dollar Bike Ride Grant Program is offering a $68,245 grant for the study of inclusion body myositis (IBM). Researchers from around the world are eligible to apply. Letters of Interest are due Friday, September 18. The grant is...
by Kevin Dooley, MD | Jun 10, 2020 | News and Information
JOIN US! On June 13, you can support the cause of inclusion body myositis by biking, walking, running, swimming, or riding in your own town or city. The Million Dollar Bike Ride has become a virtual event this year. Although it is unfortunate that Team Cure IBM cannot...
by Kevin Dooley, MD | Apr 14, 2020 | News and Information
Due to the coronavirus pandemic, Team Cure IBM will not be able to ride our bikes in Philadelphia this summer. However, although the University of Pennsylvania, the sponsor of the Million Dollar Bike Ride (MDBR), has cancelled the ride, the MDBR will still continue as...
by Kevin Dooley, MD | Mar 27, 2020 | News and Information
Thomas Blaettler, MD, the Chief Medical Office of Orphazyme, has released a statement to the global community regarding the status of the ongoing arimoclomol clinical trials during the coronavirus (COVID-19) pandemic. Arimoclomol is currently being studied for...
by Kevin Dooley, MD | Mar 20, 2020 | News and Information
The following is a message written by Tom Lloyd, MD, a myositis specialist at the Johns Hopkins Medical Center. Can Chloroquine Cure Coronavirus? Not so fast… In a press conference today, President Trump discussed what the FDA was doing to accelerate approval of...